-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | IL0011809592 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | nan |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 7 |
| PE Ratio | None |
| Market Cap | 20M |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NRSN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024